Immune Biosolutions Revenue and Competitors

Immune Biosolutions is an innovative biotech company specialized in the discovery and engineering of chicken edible and humanized antibodies that target proteins with a recognized, yet unexploited, therapeutic potential. Our focus is to change the odds of antibody discovery against traditionally difficult targets, such as GPCRs and other membranes proteins. Through its Nebula Antibody Platform, Immune Biosolutions generates high-value recombinant antibody portfolios that can target, as well as modulate, membrane proteins. Its unique discovery platform addresses all the current challenges related to GPCR and membrane protein antibody discovery by taking advantage of the untapped chicken antibody repertoire to target conserved mammalian proteins, proprietary Spatial Peptides reproducing the target's 3D conformation, phage display technologies combined with NGS to select the best recombinant antibody candidates and efficient humanization formatting. IBio applies a multi-string corporate strategy by 1) the establishment of discovery partnerships with industry leaders and emerging biotechs, and 2) the generation of an internal pipeline of first-in-class antibody candidates. Our current pipeline of therapeutic programs includes two GPCR programs known to be overexpressed in several cancers, and for which IBio is currently validating their therapeutic potential in vitro.